Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Sarepta Sells Priority Review Voucher to Gilead for $125M

Sarepta Therapeutics said today it will sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Gilead Sciences for ...

Forward this item to a colleague:


(Separate multiple addresses by commas)